Firazyr: adverse event reports filed with FDA

3,025

reports as suspect product

0% of all reports · about 186 a year

95

reports, 12 months to June 2026

98 in the 12 months before

70%

marked serious by the reporter

75.3% across the class

4.3%

record death among outcomes, as reported

130 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Firazyr reports recording the termmedian drug in bradykinin b2 receptor antagonist

1. Hereditary angioedema47.8%1,446
2. Drug ineffectivethe medicine did not work as expected9.2%278
3. Product dose omission issuea dose was missed9%273
4. Injection site painpain where the injection was given7.3%221
5. Inappropriate schedule of product administrationthe product was taken at the wrong times6.2%189
6. Weight decreasedweight loss5.5%165
7. Product use issuea problem in how the product was used5.3%160
8. Weight increasedweight gain4.4%134
9. Headachehead pain4.4%133
10. Covid-19COVID-19 infection3.9%118
11. Prescribed overdose3.7%112
12. Deaththe patient died; cause not stated by this term3.4%104
13. Pharyngeal oedemaswelling of the throat3.4%104
14. Stressstress3.4%104
15. Laryngeal oedemaswelling of the voice box3.2%98
16. Off label useused for a purpose or in a way not on the label3.2%96
17. Fatiguetiredness3.1%95
18. Malaisegeneral feeling of being unwell3.1%95
19. Falla fall3.1%93
20. Insurance issue3.1%93
21. Nauseafeeling sick3%92
22. Injection site erythemaredness where the injection was given3%91
23. No adverse eventno adverse event was reported2.7%82
24. Painpain, site not specified2.6%80
25. Pneumonialung infection2.6%80
26. Dizzinesslight-headedness or unsteadiness2.5%77
27. Dyspnoeashortness of breath2.4%73
28. Hospitalisationadmission to hospital2.4%73
29. Inappropriate schedule of drug administrationthe medicine was taken at the wrong times2.3%70
30. Illness2.1%64

Top 30 of 453 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 3 drugs in the bradykinin b2 receptor antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 5,620 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 88.1% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,025 reports.

Drugs most often listed in the same reports

Other products listed in reports where Firazyr is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the bradykinin b2 receptor antagonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Firazyr as a suspect or interacting product; reports listing it only as a concomitant medication (1,666) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.